<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306276</url>
  </required_header>
  <id_info>
    <org_study_id>DIENIVF-ENDO</org_study_id>
    <nct_id>NCT04306276</nct_id>
  </id_info>
  <brief_title>Pretreatment With Dienogest in Women With Endometriosis Undergoing in Vitro-fertilization After a Previous Failed Cycle</brief_title>
  <official_title>Pretreatment With Dienogest in Women With Endometriosis Undergoing in Vitro-fertilization After a Previous Failed Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Policlinico San Martino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Policlinico San Martino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is generally assumed that the major causes of in vitro fertilization (IVF) failure in
      women with endometriosis are diminished ovarian reserve, impaired endometrial receptivity and
      low quality of embryos. The use of prolonged courses of hormone therapy may play an important
      role in the strategy of overcoming endometriosis-related infertility. The aim of this study
      was to evaluate the use of dienogest (DNG) before an IVF cycle in women with endometriosis
      undergone a previous IVF failed cycle
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcomes of the study are clinical pregnancy rate and live birth rate after
      reaching 24 week's gestation.

      Secondary outcomes of the study are: changes in the diameter and volume of the largest
      endometrioma, total gonadotropin dose administered, number of mature oocytes collected,
      number of two-pronuclear (2PN) embryos, number of blastocysts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Live birth rate after reaching 24 week's gestation</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total gonadotropin dose administered</measure>
    <time_frame>During the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mature oocytes collected</measure>
    <time_frame>During the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of two-pronuclear (2PN) embryos</measure>
    <time_frame>During the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blastocysts.</measure>
    <time_frame>During the procedure</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">140</enrollment>
  <condition>Endometriosis</condition>
  <condition>Endometriosis Ovary</condition>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>Patients undergoing direct IVF</arm_group_label>
    <description>Patients directly undergo IVF without receiving previous hormonal treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients pretreated with DNG</arm_group_label>
    <description>Patients having received a three-month treatment with DNG before undergoing IVF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dienogest 2 MG</intervention_name>
    <description>Three-month treatment with DNG (2 mg daily; Visanne, Bayer Pharma, Germany) before IVF</description>
    <arm_group_label>Patients pretreated with DNG</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with endometriosis who previously failed one IVF cycle and all resultant frozen
        embryo transfer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of endometriosis at magnetic resonance imaging or transvaginal
             ultrasonography;

          -  one failed previous IVF cycle (including failure of frozen embryo transfer);

          -  basal FSH &lt; 14.0 IU/L;

          -  antimullerian hormone (AMH) blood level &gt;= 0.5 g/mL;

          -  normal thyroid-stimulating hormone and prolactin.

        Exclusion Criteria:

          -  history of surgery for endometriosis;

          -  history of uterine or adnexal surgery;

          -  use of hormonal therapies for the treatment of endometriosis related pain within 6
             months before IVF;

          -  adenomyosis (magnetic resonance imaging or transvaginal ultrasonography);

          -  hydrosalpinx;

          -  submucosal fibroids;

          -  body mass index (BMI) â‰¥ 30 kg/m2;

          -  severe male factor infertility (&lt; 5 million total motile sperm count).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Barra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Ospedale Policlinico San Martino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Ospedale Policlinico San Martino</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 8, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Policlinico San Martino</investigator_affiliation>
    <investigator_full_name>Fabio Barra</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

